Warning: Use of undefined constant KT_BSEO - assumed 'KT_BSEO' (this will throw an Error in a future version of PHP) in /homepages/46/d347802020/htdocs/los-angeles-dentist-blog/wp-content/plugins/keyword-tag-wrapper/keyword-tagger-bseo.php on line 10

Warning: Use of undefined constant KT_BSEO_DB_VERSION - assumed 'KT_BSEO_DB_VERSION' (this will throw an Error in a future version of PHP) in /homepages/46/d347802020/htdocs/los-angeles-dentist-blog/wp-content/plugins/keyword-tag-wrapper/keyword-tagger-bseo.php on line 11

Warning: Use of undefined constant wp_cumulus_widget - assumed 'wp_cumulus_widget' (this will throw an Error in a future version of PHP) in /homepages/46/d347802020/htdocs/los-angeles-dentist-blog/wp-content/plugins/wp-cumulus/wp-cumulus.php on line 375
Results presented today at the ESC Congress 2013 | Dentist Beverly Hills, Dentist Los Angeles
Dentist Los Angeles | Dentist Beverly Hills | General Dentist | Cosmetic Dentist | Dental Implant | Dental Office
 

www.zdentalgroup.com

 

Results presented currently during a ESC Congress 2013

Posted by Z Dental Group - August 31st, 2013

“For patients with NVAF who bear procedures, a rate of anticoagulation-related inauspicious events appears to be identical either a studious is chronically anticoagulated with apixaban or warfarin,” pronounced investigate lead questioner Dr. Renato Lopes of Duke University Medical Center in Durham, North Carolina. “For NVAF patients for whom stop of anticoagulation for a procession is required, these commentary advise that regulating apixaban instead of warfarin, that is some-more critical to stop and restart, might facilitate a government of peri-operative anticoagulation in NVAF patients.”

There were 11,417 procedures in 6,162 patients from a 18,201 patients enrolled in a ARISTOTLE trial. The many common procedures were dental extraction/oral surgery, colonoscopy, top endoscopy, and ophthalmic surgery. For 4,082 (35.8 percent) procedures, investigate drug was not stopped. In a 7,335 procedures (64.2 percent) where investigate drug was stopped, a median time of investigate drug stop was 4 days before a procession for both Eliquis and warfarin-treated patients. The procedures were personal as vital if they compulsory ubiquitous anesthesia, and procedures were also personal as emergent or non-emergent by investigators.

Among patients undergoing procedures in a ARISTOTLE trial, cadence and systemic embolism were odd and a 30-day post-procedure rates for these events were not statistically opposite in a twin diagnosis arms (0.33 percent for Eliquis vs. 0.53 percent for warfarin). Major draining occurred in a allied series of patients 30 days post-procedure in a twin diagnosis arms (1.57 percent for Eliquis vs. 1.81 percent for warfarin). In patients holding Eliquis, a rates of post-procedural cadence or systemic embolism and vital draining were identical either Eliquis was interrupted or continued. In patients holding warfarin, a rates of post-procedure vital draining and genocide seemed aloft when warfarin was continued compared to when it was interrupted.

“The stream formula do not embody analyses for particular procession forms and therefore decisions either to miscarry apixaban or warfarin before to procedures should be formed on caring of procedural draining risk and studious thrombotic risk,” pronounced Dr. Lopes. “In addition, serve analyses, including analyses according to form of procedures and timing, are ongoing to improved conclude these relationships.”

The U.S. Prescribing Information for Eliquis states that Eliquis should be dropped during slightest 48 hours before to elective medicine or invasive procedures with a assuage or high risk of unsuitable or clinically poignant bleeding. Eliquis should be dropped during slightest 24 hours before to elective medicine or invasive procedures with a low risk of draining or where a draining would be noncritical in plcae and simply controlled.

The U.S. Prescribing Information for Eliquis also includes a Boxed Warning for patients who pause treatment. Patients on Eliquis who pause diagnosis are during an increasing risk of thrombotic events.

About ARISTOTLE

The ARISTOTLE investigate was designed to denote a efficiency and reserve of Eliquis contra warfarin for a impediment of cadence or systemic embolism. In ARISTOTLE, 18,201 patients were randomized (9,120 patients to Eliquis and 9,081 to warfarin). ARISTOTLE was an active-controlled, randomized, double-blind, multi-national hearing in patients with nonvalvular atrial fibrillation or atrial flutter, and during slightest one additional risk means for stroke. Patients were randomized to diagnosis with Eliquis 5 mg orally twice daily (or 2.5 mg twice daily in comparison patients, representing 4.7 percent of all patients) or warfarin (target INR operation 2.0-3.0), and followed for a median of 1.8 years.

About Atrial Fibrillation

Atrial fibrillation is a many common cardiac arrhythmia (irregular heart beat). It is estimated that approximately 5.8 million Americans and 6 million people in Europe have atrial fibrillation. The lifetime risk of building atrial fibrillation is estimated to be approximately 25 percent for people 40 years of age or older. One of a many critical medical concerns for people with atrial fibrillation is a increasing risk of stroke, that is 5 times aloft in people with atrial fibrillation than those though atrial fibrillation. In fact, 15 percent of all strokes are attributable to atrial fibrillation in a U.S. Additionally, strokes due to atrial fibrillation are some-more fatiguing than strokes due to other causes. Atrial fibrillation-related strokes are some-more critical than other strokes, with an compared 30-day mankind of 24 percent and a 50 percent odds of genocide within one year in patients who are not treated with an antithrombotic.

About Eliquis®

Eliquis® (apixaban) is an oral approach Factor Xa inhibitor. By stopping Factor Xa, a pivotal blood clotting protein, Eliquis prevents thrombin era and blood clot formation. Eliquis is authorized to revoke a risk of cadence and systemic embolism in patients with nonvalvular atrial fibrillation in a United States, European Union (which includes 28 member states and Iceland and Norway), Japan and a series of other countries around a world. Eliquis is authorized for impediment of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee deputy medicine in a European Union (which includes 28 member states and Iceland and Norway) and a series of other countries around a world. Eliquis is not authorized for this denote in a U.S. or Japan.

IMPORTANT SAFETY INFORMATION FOR ELIQUIS

BOXED WARNING: DISCONTINUING ELIQUIS IN PATIENTS WITHOUT ADEQUATE CONTINUOUS ANTICOAGULATION INCREASES RISK OF STROKE.

Discontinuing ELIQUIS places patients during an increasing risk of thrombotic events. An increasing rate of cadence was celebrated following discontinuation of ELIQUIS in clinical trials in patients with nonvalvular atrial fibrillation. If anticoagulation with ELIQUIS contingency be dropped for a reason other than pathological bleeding, coverage with another anticoagulant should be strongly considered.

CONTRAINDICATIONS

– Active pathological bleeding

– Severe hypersensitivity greeting to ELIQUIS (apixaban) (i.e., anaphylactic reactions)

WARNINGS AND PRECAUTIONS

Increased Risk of Stroke with Discontinuation of ELIQUIS: Discontinuing ELIQUIS in a deficiency of adequate choice anticoagulation increases a risk of thrombotic events. An increasing rate of cadence was celebrated during a transition from ELIQUIS to warfarin in clinical trials in patients with nonvalvular atrial fibrillation. If ELIQUIS contingency be dropped for a reason other than pathological bleeding, cruise coverage with another anticoagulant.

Bleeding Risk: ELIQUIS increases a risk of draining and can means serious, potentially deadly bleeding. Concomitant use of drugs inspiring hemostasis increases a risk of draining including aspirin and other anti-platelet agents, other anticoagulants, heparin, thrombolytic agents, SSRIs, SNRIs, and NSAIDs. Patients should be done wakeful of signs or symptoms of blood detriment and educated to immediately news to an puncture room. Discontinue ELIQUIS in patients with active pathological hemorrhage. There is no determined approach to retreat a anticoagulant outcome of apixaban, that can be approaching to insist for about 24 hours after a final sip (i.e., about twin half-lives). A specific remedy for ELIQUIS is not available. Because of high plasma protein binding, apixaban is not approaching to be dialyzable. Protamine sulfate and vitamin K would not be approaching to impact a anticoagulant activity of apixaban. There is no knowledge with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in people receiving apixaban. There is conjunction systematic motive for annulment nor knowledge with systemic hemostatics (desmopressin and aprotinin) in people receiving apixaban. Use of procoagulant annulment agents such as prothrombin formidable concentrate, activated prothrombin formidable concentrate, or recombinant means VIIa might be deliberate though has not been evaluated in clinical studies. Activated colourless reduces fullness of apixaban thereby obscure apixaban plasma concentrations.

Prosthetic Heart Valves: The reserve and efficiency of ELIQUIS has not been complicated in patients with prosthetic heart valves and is not endorsed in these patients.

ADVERSE REACTIONS

The many common and many critical inauspicious reactions reported with ELIQUIS (apixaban) were associated to bleeding.

DISCONTINUATIONS FOR SURGERY AND OTHER INTERVENTIONS

ELIQUIS should be dropped during slightest 48 hours before to elective medicine or invasive procedures with a assuage or high risk of unsuitable or clinically poignant bleeding. ELIQUIS should be dropped during slightest 24 hours before to elective medicine or invasive procedures with a low risk of draining or where a draining would be noncritical in plcae and simply controlled.

DRUG INTERACTIONS

Strong Dual Inhibitors of CYP3A4 and P-gp: Inhibitors of CYP3A4 and P-gp boost bearing to apixaban and boost a risk of bleeding. Decrease a sip of ELIQUIS to 2.5 mg twice daily when coadministered with drugs that are clever twin inhibitors of CYP3A4 and P-gp, (e.g., ketoconazole, itraconazole, ritonavir, or clarithromycin). In patients already holding ELIQUIS during a sip of 2.5 mg twice daily, equivocate coadministration with clever twin inhibitors of CYP3A4 and P-gp.

Strong Dual Inducers of CYP3A4 and P-gp: Inducers of CYP3A4 and P-gp diminution bearing to apixaban and boost a risk of stroke. Avoid consequent use of ELIQUIS with clever twin inducers of CYP3A4 and P-gp (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) since such drugs will diminution bearing to apixaban.

Anticoagulants and Antiplatelet Agents: Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and ongoing NSAID use increases a risk of bleeding. APPRAISE-2, a placebo-controlled clinical hearing of apixaban in high-risk post-acute coronary syndrome patients treated with aspirin or a multiple of aspirin and clopidogrel, was consummated early due to a aloft rate of draining with apixaban compared to placebo.

PREGNANCY CATEGORY B

There are no adequate and well-controlled studies of ELIQUIS in profound women. Treatment is expected to boost a risk of hemorrhage during pregnancy and delivery. ELIQUIS should be used during pregnancy usually if a intensity advantage outweighs a intensity risk to a mom and fetus.

Please see full Prescribing Information including BOXED WARNING and Medication Guide accessible during www.bms.com.

About a Bristol-Myers Squibb/Pfizer Collaboration

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide partnership to rise and commercialize Eliquis, an oral anticoagulant detected by Bristol-Myers Squibb. This tellurian fondness combines Bristol-Myers Squibb’s long-standing strengths in cardiovascular drug growth and commercialization with Pfizer’s tellurian scale and imagination in this field.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a tellurian biopharmaceutical association whose goal is to discover, rise and broach innovative medicines that assistance patients overcome over critical diseases. For some-more information, greatfully revisit http://www.bms.com or follow us on Twitter during http://twitter.com/bmsnews.

Pfizer Inc.: Working together for a healthier world™

At Pfizer, we request scholarship and a tellurian resources to move therapies to people that extend and significantly urge their lives. We essay to set a customary for quality, reserve and value in a discovery, growth and make of health caring products. Our tellurian portfolio includes medicines and vaccines as good as many of a world’s best-known consumer health caring products. Every day, Pfizer colleagues work opposite grown and rising markets to allege wellness, prevention, treatments and cures that plea a many feared diseases of a time. Consistent with a shortcoming as one of a world’s premier innovative biopharmaceutical companies, we combine with health caring providers, governments and internal communities to support and enhance entrance to reliable, affordable health caring around a world. For some-more than 150 years, Pfizer has worked to make a disproportion for all who rest on us. To learn more, greatfully revisit us during www.pfizer.com.

Bristol-Myers Squibb Forward-Looking Statement

This press recover contains “forward-looking statements” as that tenure is tangible in a Private Securities Litigation Reform Act of 1995 per product development. Such forward-looking statements are formed on stream expectations and engage fundamental risks and uncertainties, including factors that could delay, obstruct or change any of them, and could means tangible outcomes and formula to differ materially from stream expectations. No forward-looking matter can be guaranteed. Among other risks, there can be no pledge that Eliquis will be authorized for a impediment and diagnosis of VTE or in a U.S. Forward-looking statements in this press recover should be evaluated together with a many uncertainties that impact Bristol-Myers Squibb’s business, quite those identified in a cautionary factors contention in Bristol-Myers Squibb’s Annual Report on Form 10-K for a year finished Dec 31, 2012, in a Quarterly Reports on Form 10-Q and a Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no requirement to publicly refurbish any forward-looking statement, either as a outcome of new information, destiny events or otherwise.

PFIZER DISCLOSURE NOTICE:

The information contained in this recover is as of Aug 31, 2013. Pfizer assumes no requirement to refurbish forward-looking statements contained in this recover as a outcome of new information or destiny events or developments. This recover contains forward-looking information about Eliquis (apixaban), including a intensity benefits, that involves estimable risks and uncertainties. Such risks and uncertainties include, among other things, (i) a uncertainties fundamental in investigate and development; (ii) uncertainties per a blurb success of Eliquis; (iii) either and when Eliquis will be authorized in a EU for a diagnosis of venous thromboembolic events (VTE) or in a U.S. and other markets for a impediment and diagnosis of VTE, as good as a decisions of regulatory authorities in those jurisdictions per labeling and other matters that could impact a accessibility or blurb intensity of those additional indications; and (iv) rival developments.

A serve outline of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K/A for a mercantile year finished Dec 31, 2012 and in a reports on Form 10-Q and Form 8-K.

Shared Post

    Tags: ,

    Leave a Reply

    You must be logged in to post a comment.

    Blog Home